Fuze Health

Overview

Fuze Health is a digital-pharmacy infrastructure platform combining FuzeRx virtual pharmacy, Alto Pharmacy partner solutions, and LetsGetChecked diagnostics for manufacturer direct-to-patient launches, hub-plus-dispensing programs, and connected patient-access workflows. Fuze Health is the active brand for the Truepill / FuzeRx / Alto Pharmacy / LetsGetChecked platform family, unified under the Fuze Health name in May 2025 after LetsGetChecked acquired Truepill (October 2024) and added Alto to the combined platform; buyers searching Truepill, FuzeRx, Alto Pharmacy, or LetsGetChecked should evaluate Fuze Health as the current operating entity.

Fuze is best read as configurable digital-pharmacy and access infrastructure, not as a classic outsourced hub replacement, a CRO, or a specialty-pharmacy network. The relevant manufacturer wedge sits inside FuzeRx (virtual pharmacy, API fulfillment, custom-branded patient experiences), Alto (Hub+, Dispensing, Complete), and Access+ (the partner model with Valeris pairing Fuze digital pharmacy with classic hub functions like benefits verification and prior authorization).

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Fuze Health is evaluated as a digital-pharmacy infrastructure vendor.

Capability	Buyer should compare	Fuze Health readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Core data foundation. FuzeRx and Alto operate API-powered virtual pharmacy, partner-owned digital front doors, and pharmacy workflow integration across nationwide fulfillment hubs.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Adjacent. Diagnostics and home-care data sit alongside the pharmacy core but are not the primary commercial-analytics use case; confirm reporting depth against incumbent CRM and data-lake vendors.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Core workflow layer. Fuze runs pharmacy workflow, adherence, engagement, and partner-led access models; the Access+ model with Valeris is the cleanest 2026 example of how Fuze layers into a heavier hub.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Core network reach. Strongest where a manufacturer needs digital pharmacy, same-day or home delivery, benefits coordination, and specialty-lite access in a single workflow.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Emerging. AI is not the buyer-facing reason to choose Fuze today; treat automation claims as workflow diligence items rather than as a differentiator.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Critical diligence point. DTP and pharmacy programs need strong controls; review licensure, data rights, escalation paths, and quality oversight by operating unit (FuzeRx / Alto / partner).
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Validate by workflow. Confirm what reporting is unified across FuzeRx, Alto, Access+, and partner-run hub work, and how it consolidates for the manufacturer’s data team.

Buyer Fit

• Launch-team fit: DTP or digitally assisted access programs where the manufacturer needs virtual pharmacy, delivery, patient engagement, and a partner-owned digital front door.
• Best-fit buyers: Pharma manufacturers, biotech launch teams, and health-system or provider organizations running same-day or home-delivery programs, branded patient access flows, or hub-plus-dispensing coordination without building the whole stack internally.
• Secondary fit: Broader patient-access models that pair Fuze’s digital pharmacy layer with a dedicated hub partner (e.g., Valeris in the Access+ model) for benefit verification, prior authorization, and case management.
• Less ideal fit: High-complexity rare disease, REMS-heavy, or deeply field-led programs where the lead requirement is a traditional high-touch hub with extensive nurse, FRM, and payer-escalation operations.
• Commercial fit: Pricing is custom / RFP; expect explicit scoping around which operating unit (FuzeRx, Alto, Access+) owns which workflow and how partner-run hub work integrates.
• Coverage diligence: Which workflows sit on FuzeRx, Alto Hub+, Access+, or partner systems; how reporting is unified; and where human review sits in benefits, copay, prior authorization, and fulfillment workflows.

Differentiators

• Unified platform for the Truepill / Alto / LetsGetChecked stack: One contract, one operating model for what used to be three separate vendor evaluations; reduces buyer friction across digital pharmacy, hub-adjacent, and home-health diagnostics workflows.
• Digital pharmacy plus access workflow: Virtual pharmacy, home delivery, refill support, patient communications, and hub-plus-dispensing operations sit in one stack, which is a different shape than analytics-first platforms.
• Named manufacturer program signals: PfizerForAll (2024), Cencora collaboration, Genentech’s Xofluza DTP program (October 2025), and the Valeris Access+ partnership (April 2026) all anchor Fuze’s manufacturer-access relevance with concrete program-level evidence.
• Partnerable access model: Access+ with Valeris formalizes Fuze as the digital-pharmacy layer inside a broader access stack — useful when a manufacturer wants a dedicated hub partner to own heavier benefits and prior authorization work.
• Broad platform adjacency: LetsGetChecked diagnostics and Veritas Genetics genomics add home-centered care and screening adjacencies, relevant for some launch models but not required for every pharma program.

RFP Questions

• Which part of the proposed workflow runs on FuzeRx, Alto Hub+, Access+, or a partner-operated hub platform?
• What pharmacy licenses, payer connections, data rights, and patient-consent controls are included in the proposed program?
• How are benefits investigation, prior authorization, copay support, refill reminders, and adherence workflows divided between software automation and human review?
• What reporting is available by patient status, fulfillment status, abandonment reason, payer issue, coupon use, and time to therapy?
• How does the operating model change for specialty, cold-chain, limited-distribution, or controlled-substance products?

Recent Activity

• Oct 2024 - LetsGetChecked completed its acquisition of Truepill, bringing virtual pharmacy and B2B pharmacy infrastructure into the same platform.
• Oct 2024 - Alto launched Alto Technologies, formalizing Hub+, Dispensing, and Complete as partner-facing solutions.
• May 2025 - Fuze Health formally launched as the unified entity combining LetsGetChecked, Truepill, and Alto capabilities.
• Oct 2025 - Genentech launched an Xofluza direct-to-patient program using Alto Pharmacy powered by Fuze Health.
• Mar 2026 - Fuze Health’s Veritas Genetics unit joined an Illumina consortium focused on population-scale whole-genome sequencing through health-plan channels.
• Mar 2026 - Point32Health notified providers that new impacted Harvard Pilgrim and Tufts fertility-medication prescriptions would transition from Optum Specialty Pharmacy to Fuze Health after Optum exited fertility dispensing.
• Apr 2026 - Valeris and Fuze Health announced a connected patient access collaboration pairing Fuze’s digital pharmacy operations with Valeris access-services support.